Navigation Links
Unigene to Announce Fourth Quarter and Full-Year 2011 Financial Results on March 8, 2012
Date:3/1/2012

BOONTON, N.J., March 1, 2012 /PRNewswire/ -- Unigene Laboratories, Inc. (OTCBB: UGNE), a leader in the design, delivery, manufacture and development of peptide-based therapeutics announced today that the Company's senior management team will host a conference call and live audio webcast on Thursday, March 8, 2012 at 11 a.m. ET to discuss fourth quarter and full-year 2011 financial results.

Interested participants and investors may access the conference call at 11 a.m. ET by dialing 866-277-1181 (U.S./Canada) or 617-597-5358 (international); participant code 82583482.  An audio webcast can be accessed by logging on to the Investors and Media section under the Events tab of the Unigene web site, http://www.unigene.com.  

A telephonic replay of the call will be available for two weeks beginning at 2 p.m. ET on March 8.  Access numbers for this replay are 888-286-8010 (U.S./Canada) and 617-801-6888 (international); participant code 18902945. The webcast replay will remain available in the Investors section of the Unigene Laboratories web site for 30 days.

About Unigene Laboratories, Inc.

Unigene Laboratories, Inc. is a leader in the design, delivery, manufacture and development of peptide-based therapeutics. The Company is building a robust portfolio of proprietary partnerships in this expanding drug class based on its Peptelligence™ platform.  Peptelligence encompasses extensive intellectual property covering delivery and manufacturing technologies, unsurpassed research and development expertise, and proprietary know-how representing a genuine distinctive competence. Core Peptelligence assets include proprietary oral and nasal peptide delivery technologies, and proprietary, high-yield, scalable and reproducible E. coli-based manufacturing technologies.

Investor Contact:
Unigene Laboratories, Inc.
Jenene Thomas
VP, Investor Relation
'/>"/>

SOURCE Unigene Laboratories, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Unigene Receives 2012 Drug Delivery Partnerships Industry Achievement Award
2. Unigenes 2011 Year in Review - Key Elements in Place to Address Debt in 2012
3. Unigene to Present at the Oppenheimer 22nd Annual Healthcare Conference on December 13, 2011
4. Unigene Announces Positive Top-Line Results of Phase 2 Oral PTH Study for the Treatment of Osteoporosis in Postmenopausal Women
5. Tarsa Therapeutics and Unigene Present Preclinical Data Suggesting Calcitonin May Have Utility in Combination Therapy for the Treatment of Osteoarthritis
6. Updated: Life Technologies Announces Fourth Quarter and Fiscal Year 2011 Results
7. ARUP Laboratories Announces Creation of Business Innovations Division
8. City of Mason and Top Gun Sales Performance Announce $4 Million Investment In New Corporate Headquarters
9. BioSpecifics Technologies Corp. Announces Presentations at Two Upcoming Investor Conferences in March
10. Regeneron Announces March 2012 Investor Conference Presentations
11. MiMedx Group Announces 2011 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/1/2015)...  Among 1,050 U.S. consumers, the majority knows little ... and only 36 percent reported being screened for oral ... from a survey released today by  Vigilant ... of solutions that aid in the early detection and ... 1,050 U.S. consumers on their knowledge of risk factors ...
(Date:4/1/2015)... YORK , April 1, 2015 ... advancing protein biologic therapies and oncology supportive care ... 2014 achievements and a strategic update for 2015. ... Company has made in the areas of business ... programs, the FDA clearance of the ProctiGard product, ...
(Date:4/1/2015)... YORK CITY and LONDON , ... market research reports and solutions, MarketResearch.com is pleased to highlight ... be a year of market growth and opportunity for the ... cell company or cord blood bank, competing in the stem ... conditions, predict industry trends, and act on market changes before ...
(Date:4/1/2015)... April 1, 2015 Immunocore ... novel biological drugs to treat cancer, viral infections ... the appointment of Christina Coughlin as ... for providing medical and regulatory leadership to the ... Dr. Coughlin has extensive experience in oncology ...
Breaking Biology Technology:National Oral Cancer Awareness Survey Reveals Greater Need for Education and Screening Tools for Oral Cancer Among U.S. Adults 2National Oral Cancer Awareness Survey Reveals Greater Need for Education and Screening Tools for Oral Cancer Among U.S. Adults 3National Oral Cancer Awareness Survey Reveals Greater Need for Education and Screening Tools for Oral Cancer Among U.S. Adults 4PlasmaTech Biopharmaceuticals Provides Strategic Update for 2015 and Review of 2014 Acheivements 2PlasmaTech Biopharmaceuticals Provides Strategic Update for 2015 and Review of 2014 Acheivements 3PlasmaTech Biopharmaceuticals Provides Strategic Update for 2015 and Review of 2014 Acheivements 4PlasmaTech Biopharmaceuticals Provides Strategic Update for 2015 and Review of 2014 Acheivements 5PlasmaTech Biopharmaceuticals Provides Strategic Update for 2015 and Review of 2014 Acheivements 6MarketResearch.com: "Blockbuster" Year for Stem Cells Creates Market Opportunities, Says BioInformant Worldwide Report 2MarketResearch.com: "Blockbuster" Year for Stem Cells Creates Market Opportunities, Says BioInformant Worldwide Report 3MarketResearch.com: "Blockbuster" Year for Stem Cells Creates Market Opportunities, Says BioInformant Worldwide Report 4Immunocore Appoints Dr. Christina Coughlin as Chief Medical Officer 2Immunocore Appoints Dr. Christina Coughlin as Chief Medical Officer 3Immunocore Appoints Dr. Christina Coughlin as Chief Medical Officer 4
... Genstruct Inc., a,biotechnology company translating the complexity of human ... Matthews,(age 25), manager of its Scientific Programs, was selected ... 30." "We are proud to have a young, ... Dr. Keith O. Elliston, president and CEO at,Genstruct. "She ...
... Now for Exclusion of Venous Thromboembolism -, ... announced that the US Food and Drug Administration ... use for HemosIL D-Dimer HS,to exclude venous thromboembolism ... and pulmonary embolism (PE), when used in conjunction,with ...
... N.J., Oct. 9 A homegrown New Jersey ... safeguards,the pedigree of pharmaceuticals everywhere. Secure Symbology, (http://www.securesymbology.com ... chosen as an,Honored Finalist as Emerging Business of ... recognized for its vision to wipe out counterfeit ...
Cached Biology Technology:Genstruct's Andrea Matthews Selected for Mass High Tech's 'People to Watch Under 30' 2Instrumentation Laboratory Receives FDA Clearance to Expand the Intended Use for HemosIL(R) D-Dimer HS Assay 2Secure Symbology: Making New Jersey Proud While Saving Lives 2
(Date:3/20/2015)... , Mar. 19, 2015 Research and Markets ... "Hand Geometry - Global Strategic Business Report" report to ... for Hand Geometry in US$ Thousands. The report provides separate ... Japan , Europe , ... , and Rest of World. Annual estimates and ...
(Date:3/17/2015)... , March 17, 2015 MedNet ... specializing in clinical study management systems, is pleased ... attendance at ARENA,s Outsourcing in Clinical Trials Southeast ... event provides an excellent forum for MedNet to ... and affordable software-as-a-service (SaaS) eClinical technology platform. ...
(Date:3/12/2015)... WINSTON-SALEM, N.C. , March 12, 2015 ... afternoon at Brenner Children,s Hospital, part of Wake Forest ... an outreach initiative for the 2015 ACC Men,s Basketball ... taking pictures with them and getting their autographs. ... Wake Forest Baptist. It is the only children,s hospital ...
Breaking Biology News(10 mins):Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 2Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 3Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 4Connect With MedNet Solutions At Outsourcing In Clinical Trials Southeast 2
... Virginia Tech released today results from the first study ... are currently designed to the same standards as adult ... football players impact their heads. This is the first ... football, and will greatly enhance the development of improved ...
... is difficult to measure accurately each nation,s contribution of carbon ... the ground as coal, gas, and oil, and these fuels ... to generate the energy that is used to make products. ... countries where they are consumed. A team led by Carnegie,s ...
... George Georgiou, a professor at The University of Texas ... and cellular fields could help treat tens of thousands of ... elected as a member of the Institute of Medicine (IOM). ... the National Academies. Induction into the institute is considered one ...
Cached Biology News:Virginia Tech biomedical engineers announce child football helmet study 2Virginia Tech biomedical engineers announce child football helmet study 3Links in the chain: Global carbon emissions and consumption 2UT professor elected to the Institute of Medicine of the National Academies 2UT professor elected to the Institute of Medicine of the National Academies 3
Gentamicin sulfate, 5g...
Rabbit Anti-melatonin (different linkage) Polyclonal Antibody...
... Product Goat polyclonal to ... (Microorganism). Reactivity / Specificity Cross-reacts ... species. Background Information Cholesterol oxidases ... II oxidases and are implicated in bacterial ...
Rabbit polyclonal to SERHL ( Abpromise for all tested applications). entrezGeneID: 94009 SwissProtID: Q9H4I8...
Biology Products: